Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. It is around half the potency of dexamphetamine, and is prescribed at a dose... It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose.
- Mechanism
- Curator reviewed
Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The drug seems to inhibit the dopamine transporter (DAT) that removes dopamine from the synapses. This inhibition of DAT blocks the reuptake of dopamine and norepinephrine into the presynaptic neuron, increasing the amount of dopamine in the synapse. It also stimulates the release of dopamine and norepinephrine into the synapse. Finally, it increases the magnitude of dopamine release after a stimulus, increasing the salience of stimulus. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer. Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.
- Primary indication
- For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.Curator reviewed
- Formula / weight
- C15H21N · 215.3339 g/mol (avg)
- Also known as
- Phencamphamine
- Code names
- DEA No. 1760
Resolves to
IKFBPFGUINLYQI-UHFFFAOYSA-NSMILESCCNC1C2CCC(C2)C1C1=CC=CC=C1What you can answer from here — as of September 16, 2026
Which drugs share a target with Fencamfamin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account